Cardiovascular Protective Effect of Spironolactone in Hemodialysis

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

• Phase: Phase 4

Details

• Lead Sponsor: Universidad de los Andes, Chile; Universidad Los Andes, Chile
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

chronic hemodialysys (> 3 months) anuria (diuresis <200 mL/day) -

Exclusion Criteria:

Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists Cancer

-